1 TuP24:W16 ) Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezethnibe and SimVaStathl

Results: Efficacy evaluated cases were 565. LDL-cholesterol was reduced by 20.7 f 0.6 (SE)% in 8-12 weeks studies (n = 426), and by 19.0 f 1.5% in 48 weeks study (n = 55). HDL-cholesterol was increased by 7.7 f 0.8%, and by 11.6 f 2.7%, respectively. In phase III 12 weeks study, 3.0 g daily dose, a common dose of colestilan in Japan reduced LDL-C by 21.9 f 1.2% (n = 94) and increased HDL-C by 8.4 f 1.5% (n = 98). Safety was evaluated in 642. Side effects were observed in 150 patients (23.4%), mainly constipation and flatulent feelings. Transient and slight elevation of GOT and GPT was observed in 2.7% and 4.3%. respectively. Definite drug interaction was not observed. Conclusions: Colestilan is a new bile acids sequestrant resin improved in drug formation and dose, and is expected as an agent in independent or concomitant therapy in hypercholesterolaemia. Colestilan developed by Mitsubishi-Tokyo Pharmaceuticals, inc. was on the market in 1999 in Japan.